Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues

Journal of Medicinal Chemistry

Volumn 44, Issue 16, 2001, Pages 2511-2522

  Van der Mey, M ^a,b   Hatzelmann, A ^c   Van der Laan, I J ^b   Sterk, G J ^b   Thibaut, U ^c   Timmerman, H ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Byk Nederland   (Netherlands)

^c ALTANA PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZYL 4 (3,4 DIMETHOXYPHENYL) 4A,5,6,7,8,8A HEXAHYDRO 2H PHTHALAZIN 1 ONE; 2 BENZYL 4 (3,4 DIMETHOXYPHENYL) 4A,5,8,8A TETRAHYDRO 2H PHTHALAZIN 1 ONE; 4 (3,4 DIMETHOXYPHENYL) 2 PHENYL 4A,5,8,8A TETRAHYDRO 2H PHTHALAZIN 1 ONE; 4 (3,4 DIMETHOXYPHENYL) 2H PHTHALAZIN 1 ONE; 5' NUCLEOTIDASE; 6 (3,4 DIMETHOXYPHENYL) 4,5 DIHYDRO 2H PYRIDAZIN 3 ONE; CYCLIC AMP; PHOSPHODIESTERASE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHTHALAZINE DERIVATIVE; PYRIDAZINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; BINDING SITE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MODEL; NEUTROPHIL; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; BLOOD PLATELETS; ENZYME INHIBITORS; HUMANS; LEUKOCYTES; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHTHALAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035797371     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm010837k     Document Type: Article

References (59)

1. New aspects of asthma
2. Asthma: What is there left to find out?
3. Inflammatory cells and eosinophilic activity in asthmatics investigated by the bronchoalveolar lavage
4. Inflammatory cells and their mediators in the pathogenesis of asthma
5. Basic mechanisms of asthma: Role of inflammation
6. Mucosal inflammation in asthma
7. Theophylline: Recent advances in the understanding of its mode of action and uses in clinical practice
8. Tolerability of leukotriene modifiers in asthma - A review of clinical experience
9. Adenosine 3′,5-′phosphate in biological materials. I. Purification and properties of cyclic 3′,5′nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3′,5-phosphate in human urine
10. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
11. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
12. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase
13. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase
14. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
15. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase
16. Multiple cyclic nucleotide phosphodiesterases
17. Identification and quantification of PDE isoenzymes and subtypes by molecular biological methods
18. PDE4 inhibitors 1998
19. Prospects for selective cyclic nueleotide phosphod/esterase inhibitors in the treatment of bronchial asthma
20. Phosphodiesterase isozymes. Molecular targets for novel antiasthma agents
21. Phosphodiesterase inhibitors: New opportunities for treatment of asthma
22. Interaction of PDE4 inhibitors with enzymes and cell functions
23. Selective phosphodiesterase inhibitors for the treatment of bronchial asthma and chronic obstructive pulmonary disease
24. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?
25. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus
26. Phosphodiesterase isozymes modulating inherent tone in human airways: Identification and characterization
27. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: Biochemical and pharmacological analysis using selective inhibitors
28. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle
29. Zardaverine as a selective inhibitor of phosphodiesterase isoenzymes
30. 1. Phosphodiesterase type IV inhibitors
31. Electron deficient heteroaromatic ammonioamidates. XXIII. Heteroaromatic ammonioamidates with bridge-head ammonium nitrogen
32. The synthesis of phenanthrene and hydrophenanthrene detivatives. IV. Hydroxylated compounds
33. Podophyllotoxin
34. The constituents of natural phenolic resins. Part XI. Synthesis of 2- and 3-methyl-6:7-dimethoxy-1-veratrylnaphthalenes
35. 6-(substituted phenyl)-5-methyl-4,5-dihydro-pyridazin-3(2H)-ones of medicinal interest. The synthesis of SK&F 94836 and SK&F 95654
36. Ueber eine neue darstellungsweise einiger lactone der fettreihe
37. 6-Phenyl-4,5-dihydro-3(2H)-pyridazinones. A series of hypotensive agents
38. The symmetrical dimethylsuccinic acids. B. Behaviour of the dimethylsuccinic acids on distillation at the ordinary atmospheric pressure
39. The constituents of guaiacum resin. Part I. Synthesis of pyroguaiacin methyl ether
40. 1:2-Dicarboxylic acids. Part II. The diastereoisomeric αα′-dimethyl-succinic acids and their derivatives. Effect of conformation on stability
41. Ueber 2,3-dioxyanthracen
42. Darstellung basisch substituierter pyridaz-6-one
43. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Ca
44. An improved assay of cyclic 3′,5′nucleotide phosphodiesterase with QAE Sephadex A-25
45. Cardiotonic agents. 1. 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3-(2H)-pyridazinones: Novel positive inotropic agents for the treatment of congestive heart failure
46. Cardiotonic agents. 8. Selective inhibitors of adenosine 3′,5′-cyclic phosphate phosphodiesterase. Elaboration of a five-point model for positive inotropic activity
47. Stereochemical studies-XIV: Cyclic amino alcohols and related compounds-VII
48. TVX 2706 - A new phosphodiesterase inhibitor with antiinflammatory action. Biochemical characterization
49. Structure-activity relationships of quinazolinedione inhibitors of calcium-independent phosphodiesterase
50. Novel pyrazolo, isoxazolo, and thiazolo steroidal systems and model analogs containing dimethoxyaryl (or dihydroxylaryl) groups and derivatives. Synthesis, spectral properties, and biological activity
51. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2(1-lmidazolyl)alkyl]-1(2H)-phthalazinones
52. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme